CL2009000022A1 - Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante. - Google Patents

Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante.

Info

Publication number
CL2009000022A1
CL2009000022A1 CL2009000022A CL2009000022A CL2009000022A1 CL 2009000022 A1 CL2009000022 A1 CL 2009000022A1 CL 2009000022 A CL2009000022 A CL 2009000022A CL 2009000022 A CL2009000022 A CL 2009000022A CL 2009000022 A1 CL2009000022 A1 CL 2009000022A1
Authority
CL
Chile
Prior art keywords
von willebrand
factor
willebrand factor
procedure
human
Prior art date
Application number
CL2009000022A
Other languages
English (en)
Inventor
Ristol Debart Pere
Mercedes Faro Tomas Maria
Ignacio Jorquera Nieto Juan
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39316136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000022(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of CL2009000022A1 publication Critical patent/CL2009000022A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0017—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

EL PROCEDIMIENTO SE CARACTERIZA POR LA PREPARACIÓN DE UNA SOLUCIÓN DE FACTOR VON WILLEBRAND O DE COMPLEJO DE FACTOR VIII/ FACTOR VON WILLEBRAND QUE CONTIENE FVW A UNA CONCENTRACIÓN DE HASTA 12 UI FVWRC0/M1 Y UNA PROPORCIÓN ENTRE FACTOR VON WILLEBRAND/FACTOR VIII SUPERIOR O IGUAL A 0,4; Y PROCEDER A CONTINUACIÓN A LA NANOFILTRACIÓN DE LA SOLUCIÓN PREPARADA EN A) MEDIANTE UN FILTRO DE TAMAFIO DE PORO MENOR DE 35 NANÓMETROS.
CL2009000022A 2008-01-08 2009-01-07 Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante. CL2009000022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200800021A ES2298096B1 (es) 2008-01-08 2008-01-08 Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.

Publications (1)

Publication Number Publication Date
CL2009000022A1 true CL2009000022A1 (es) 2009-11-20

Family

ID=39316136

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000022A CL2009000022A1 (es) 2008-01-08 2009-01-07 Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante.

Country Status (17)

Country Link
US (2) US8354505B2 (es)
EP (1) EP2078730B9 (es)
JP (1) JP4976366B2 (es)
CN (1) CN101480490B (es)
AR (1) AR072441A1 (es)
AT (1) ATE509031T1 (es)
AU (1) AU2008255137C1 (es)
BR (1) BRPI0900057B8 (es)
CA (1) CA2645701C (es)
CL (1) CL2009000022A1 (es)
ES (2) ES2298096B1 (es)
HK (1) HK1129075A1 (es)
MX (1) MX2008015892A (es)
NZ (1) NZ573400A (es)
PL (1) PL2078730T3 (es)
PT (1) PT2078730E (es)
RU (1) RU2417096C2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN105816858A (zh) 2007-12-28 2016-08-03 巴克斯特国际公司 重组vwf配方
AU2009307648C1 (en) 2008-10-21 2016-12-08 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
KR20190041032A (ko) * 2011-06-10 2019-04-19 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
JP5711369B2 (ja) 2011-06-24 2015-04-30 旭化成メディカル株式会社 蛋白製剤の製造方法
BR112014017165B1 (pt) * 2012-01-12 2023-05-02 Bioverativ Therapeutics Inc Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos
EP2841451A1 (en) 2012-04-24 2015-03-04 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
AU2014346343B2 (en) * 2013-11-08 2018-05-10 Csl Ltd. New method to concentrate von Willebrand factor or complexes thereof
RU2714154C2 (ru) * 2014-06-06 2020-02-12 Октафарма Аг Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
CN104804078B (zh) * 2015-05-05 2019-01-04 广东卫伦生物制药有限公司 人体血清凝血因子ⅷ中的病毒过滤方法
KR20200038309A (ko) 2017-08-23 2020-04-10 체에스엘 베링 게엠베하 폰 빌레브란트 인자의 바이러스 여과 방법
CA3228445A1 (en) 2021-08-11 2023-02-16 Salvador Grancha Gamon Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
EP0860444A1 (en) * 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
FR2772381B1 (fr) * 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu

Also Published As

Publication number Publication date
ES2298096A1 (es) 2008-05-01
CN101480490A (zh) 2009-07-15
ES2298096B1 (es) 2009-01-01
RU2417096C2 (ru) 2011-04-27
BRPI0900057B8 (pt) 2021-06-29
MX2008015892A (es) 2009-07-07
BRPI0900057B1 (pt) 2021-03-23
EP2078730B9 (en) 2011-12-21
ATE509031T1 (de) 2011-05-15
PL2078730T3 (pl) 2011-10-31
JP4976366B2 (ja) 2012-07-18
EP2078730B1 (en) 2011-05-11
US20110275570A1 (en) 2011-11-10
CA2645701C (en) 2013-09-17
US8354505B2 (en) 2013-01-15
CN101480490B (zh) 2013-05-29
AU2008255137B2 (en) 2011-04-07
CA2645701A1 (en) 2009-07-08
EP2078730A1 (en) 2009-07-15
US20090176709A1 (en) 2009-07-09
JP2009161528A (ja) 2009-07-23
AR072441A1 (es) 2010-09-01
BRPI0900057A2 (pt) 2009-09-22
HK1129075A1 (en) 2009-11-20
PT2078730E (pt) 2011-07-14
AU2008255137C1 (en) 2015-08-27
NZ573400A (en) 2010-02-26
AU2008255137A1 (en) 2009-07-23
ES2363827T3 (es) 2011-08-17
RU2008151957A (ru) 2010-07-10

Similar Documents

Publication Publication Date Title
CL2009000022A1 (es) Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante.
PE20160781A1 (es) Formulaciones de insulina de accion prolongada
ECSP10010370A (es) Preparacion de solucion que contiene anticuerpos en una alta concentracion
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
AR063892A1 (es) Particulas de suministro que contienen agentes beneficos
AR084770A1 (es) Absorcion de oxigeno y dioxido de carbono en un recipiente de un solo uso con un soporte absorbente debajo del filtro
ES2687651T3 (es) Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
MY150838A (en) Oral care compositions for use with an oral light device
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
AR065963A1 (es) Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso
CL2015003634A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
MX361155B (es) Cocleatos hechos con fosfatidilserina de soja.
MX2016002492A (es) Composiciones bioactivas derivables de concentrados de plaquetas, y metodos para prepararlas y usarlas.
CO6331291A2 (es) Peptidos de señalizacion de la crkl
AR085169A1 (es) Absorcion de oxigeno y dioxido de carbono en un contenedor de uso individual
PE20120169A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
CY1108521T1 (el) Παρασκευη αλδεσλευκινης για φαρμακευτικη χρηση
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
AR100618A1 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EA201100730A1 (ru) Комплекс включения пиноцембрина с циклодекстрином, способ его получения и применения
CL2019003459A1 (es) Métodos de cultivo celular.
AR067352A1 (es) Preparado de fruta estable con elevada concentracion de goma de acacia
AR093605A1 (es) Composicion liquida de limpieza para superficies duras
PE20151085A1 (es) Composicion de xantofilas